Catalog: | C-FC-1722A |
Product Type: | FCM Antibody |
Size: | 20 tests/50 tests/100 tests/200 tests |
Reactivity: | Human |
Analysis mode: | FCM |
Host: | Mouse |
Isotype: | Mouse IgG2b, κ |
Alternate names: | GA733-2,M1S2,M4S1,MIC18,TACSTD1, TROP1 |
Form: | Liquid |
Shipping: | Biological ice pack at 4℃ |
Storage: | 2-8℃ |
Conjugation: | PE/Cyanine5 |
Buffer: | PBS with 0.05% Proclin300, 1% BSA |
Swiss port: | P16422 |
Clone NO.: | 9C4 |
Recommended use: | Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The amount of the reagent is suggested to be used 2 μL or 5 μL of antibody per test (million cells in 100 μL staining volume or per 100 μL of whole blood). Please check your vial before the experiment. Since applications vary, the appropriate dilutions must be determined for individual use. |
CD326 is also known as Ep-CAM, tumor associated calcium signal transducer 1, epithelial cell surface antigen, epithelial glycoprotein 2, EGP2, adenocarcinoma associated antigen, and TROP1. CD326 is a type I transmembrane protein containing six disulfide bridges and one THYRO domain. This cell surface glycosylated 40 kD protein is highly expressed in bone marrow, colon, lung, and most normal epithelial cells and is expressed on carcinomas of gastrointestinal origin. Recently, it has been reported that CD326 expression occurs during the early steps of erythrogenesis. CD326 functions as a homotypic calcium-independent cell adhesion molecule and is believed to be involved in carcinogenesis by its ability to induce genes involved in cellular metabolism and proliferation. CD326 antigen is an immunotherapeutic target for the treatment of human carcinomas.
Copyright © 2024 Creative Biogene. All rights reserved.